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Malignant peripheral nerve sheath tumor (MPNST) is a rare high-grade soft tissue sarcoma. The epithelioid variant accounts for
5% or less of MPNSTs; the clinical behavior of this variant is unclear. Reports of approximately 40 cases are available in the English
literature; however, most reports addressed clinicopathological features rather than therapeutic procedures or clinical courses. We
describe a case of a 62-year-old male with an epithelioid MPNST of the left foot. Multiple lung metastases developed after radical
surgery on the primary lesion. The response to adjuvant chemotherapy including doxorubicin and ifosfamide was favorable, and
thoracoscopic resection was subsequently performed on the remaining three metastases. No evidence of recurrence or metastasis
was observed at the 12-month followup after the ﬁrst operation. Further followup and chemotherapy may be required.
1.Introduction
Malignant peripheral nerve sheath tumor (MPNST) is a rare
malignant soft tissue tumor. Its variants include rhabdomy-
oblastic, glandular, and epithelioid MPNST [1]. Epithelioid
MPNST (EMPNST) accounts for 5% or less of MPNSTs
[1]. Approximately 40 cases of EMPNST have been reported
in the English literature [2–5]. Most reports address clin-
icopathological features; however, few reports are available
on advanced EMPNST with precise treatment procedures.
Here, we report an additional case of EMPNST arising in
the foot and involving lung metastases that showed complete
response to combined surgery and chemotherapy.
2. Case Presentation
A 62-year-old male without neuroﬁbromatosis presented
with an enlarging, painful mass in the third web space of
his left foot. The lesion was ﬁrst noticed approximately ﬁve
years earlier as a nodular lesion that was then diagnosed as
an epidermal cyst of the sole at a dermatologic clinic. Neither
excision nor biopsy was performed at that time. On exam-
ination, there was a ﬁrm, round mass measuring 9 × 7cm
in the third web space (Figure 1). The mass was immobile
against the surrounding bones and adhered to the overlying
skin. Multiple swollen lymph nodes were palpable in the
left inguinal region. An open biopsy was performed, which
showed proliferation of epithelioid round cells with cellular
atypia, indicating probable malignant melanoma. Radio-
logical examination including ﬂuorodeoxyglucose positron
emission tomography showed no evidence of deﬁnite distant
metastasesexceptleftinguinalregion(Figures2(a)and2(b)).
Therefore, surgical treatment was planned under the diag-
nosis of T4aN2bM0, stage III-C malignant melanoma
according to the American Joint Committee on Cancer
classiﬁcation.2 Case Reports in Oncological Medicine
Figure 1: Preoperative view showing an enlarging mass in the third
web space.
The ﬁrst operation was performed under general anes-
thesia. Left inguinal dissection was carried out (Figure 3(a)),
and an adequately wide excision of the primary tumor with
a 30mm surgical margin (i.e., transmetatarsal amputation)
wasperformed(Figure 3(b)).Theresultantrawsurfaceofthe
stumpwastemporarilycoveredwithanartiﬁcialdermis.One
week postoperatively, the stump was resurfaced with a free
latissimusdorsimusculocutaneousﬂapwithasplit-thickness
skin graft following histological conﬁrmation of adequate
surgical margins (Figure 3(c)). Although partial necrosis of
theﬂapwasobserved postoperatively, applicationofanaddi-
tional split-thickness skin graft under local anesthesia led
to complete wound healing. The specimen showed nodular
growth of the lesion measuring 70 × 43mm between the
dermis and subcutaneous layer without continuity to the
epidermis. Histologically, the lesion consisted of two com-
ponents: proliferation of spindle cells with some diﬀerenti-
ation to nerve cells, reminiscent of conventional malignant
schwannoma (Figure 4(a)), and epithelioid proliferation of
round-to-polygonal or rhabdoid cells with hyperchromatic
nuclei, reminiscent of malignant melanoma (Figures 4(b)
and 4(c)). Tumor cells stained positive for S-100 protein
and negative for HMB45 (Figure 4(d)). All dissected lymph
nodes were free of sarcoma. Based on these histological
features, the lesion was diagnosed as EMPNST, of which
histological grade was classiﬁed as grade 3 according to
the FNCLCC system (tumor diﬀerentiation: score 3, mitotic
count: score 2, and tumor necrosis: score 1).
Ten weeks after the ﬁrst operation, computed tomogra-
phy demonstrated the development of multiple small bilat-
eral lung nodules (Figures 5(a) and 5(b)). No further evi-
dence of metastasis to other organs was observed. Systemic
adjuvant chemotherapy consisting of doxorubicin and ifos-
famide was then initiated. Doxorubicin (60mg/m2)a n d
ifosfamide(7.5g/m2)withmesna(Uromitexan)wereadmin-
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Figure 2: Preoperative positron emission tomography. (a) Abnor-
mal uptake involving the aﬀected foot. (b) No abnormal uptake was
observed except left inguinal region.
istered. After two courses of the adjuvant therapy, follow-
up computed tomography revealed a good response to all
abnormal shadows; however, two lesions in segment 8 and
one in segment 10 of the left lung ﬁeld were still observable
(Figures 6(a) and 6(b)). Because these three lesions were
located just beneath the pleura, tumors were resected during
thoracoscopic surgery ﬁve months after the ﬁrst operation.
Histological examination revealed complete necrosis of the
tumor cells in one lesion and metastases of EMPNST in the
other two lesions. At the 12-month followup after radical
surgery of the primary tumor, during which time fourCase Reports in Oncological Medicine 3
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Figure 3: Intraoperative views of ablative surgery and secondary reconstructive surgery. (a) Ipsilateral inguinal dissection at the ﬁrst
operation. (b) Wide excision of the primary lesion with a 30mm surgical margin. (c) Free latissimus dorsi musculocutaneous ﬂap transfer
to the amputated stump.
(a) (b) (c)
(d)
Figure 4: Histological ﬁndings. (a) Proliferation of spindle cells with abnormal mitotic activities reminiscent of conventional malignant
schwannoma(hematoxylin-eosin,×400).(b),(c)Epithelioidfeaturesofround-to-polygonalorrhabdoidcellswithcellularatypiaresembling
malignant melanoma (hematoxylin-eosin, ×400). (d) Immunohistochemical staining demonstrating strongly positive for S-100 protein.
courses of adjuvant chemotherapy and a thoracic surgery
were added, no signs of local recurrence or metastasis were
observed (Figures 7(a) and 7(b)). The patient maintained
ambulation without a brace (Figure 8).
3. Discussion
Most MPNSTs are generally considered high-grade sarco-
mas [1]. Approximately 40% of patients developed local
recurrence, and the overall ﬁve-year survival rate was
34–43% [6, 7]. On the other hand, epithelioid variants
are rare and are estimated to comprise 5% or fewer of
MPNSTs [1]. Thus, biologic behavior and prognosis are
unclear. However, the largest series, which included 26
cases and was reported by Laskin et al. [3], showed that
although most patients were treated with wide excision,
four developed distant metastases and three died of the
disease within three years. High incidence of metastasis
(seven of 14 cases) was also reported by Lodding et al. in
1986 [2].4 Case Reports in Oncological Medicine
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Figure 5: Ten weeks after the ﬁrst operation. (a), (b) Development of multiple lung metastases (M1, M2, M3).
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Figure 6: After two courses of adjuvant chemotherapy showing good response to all metastases. Note M3 was not recognizable.
(a) (b)
Figure 7: Twelve months after the ﬁrst operation. All metastatic lesions were eliminated through the chemotherapy and thoracic surgery.
Aggressive surgery is considered the only procedure to
improve prognosis of the MPNST [6, 7], and the response to
chemotherapy against MPNST is poor according to previous
reports [8]; however, several reports have demonstrated that
chemotherapycanbeeﬀective[9,10].Althoughthestandard
regimens are still investigative, ifosfamide and doxorubicin
are considered key drugs for advanced soft tissue sarcomas
[11, 12]. In our clinical case, administering ifosfamide and
doxorubicin with mesna showed good eﬃcacy on the mul-
tiple lung metastases, with low-grade toxicities including
myelosuppression and hair loss.
Surgical management of lung metastases may be eﬀective
in select situations [13]. Two reports on MPNST demon-
strated poor survival rates after development of pulmonary
metastases; however, prolonged survived cases with thoraco-
tomy were also described [7, 8]. As for nonosteogenic sar-
coma, Creagan showed the overall 5-year survival following
the ﬁrst thoracotomy was 29% with a median survival of
18 months [14]. The present case involved the development
of disseminating lung nodules ten weeks postoperatively;
however, chemotherapy provided a favorable response to
all metastatic lesions. Subsequently, thoracoscopic resection
of the remaining three lesions was performed to both
eliminate the sarcoma and allow histological evaluation of
the response to chemotherapy. Based on the histological
ﬁndings that two of the three lesions showed remainingCase Reports in Oncological Medicine 5
Figure 8: Clinical view at 12 month postoperatively.
sarcoma, continuing the same regimen without surgery
may risk inducing development of chemotherapy-resistant
sarcoma cells.
4. Conclusions
An extremely rare case of advanced EMPNST was reported.
Multiple metastases to both lungs developed despite the
adequately wide excision of the primary tumor. How-
ever, adjuvant chemotherapy and thoracoscopic resection
yielded a favorable and complete response at the 12-month
followup.
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